Vimarsana
Biggest News Aggregation in the World

Current Reports News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Current Reports. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Current Reports Today - Breaking & Trending Today

Targa Resources Corp. to Participate in J.P. Morgan Energy, Power and Renewables Conference - Vimarsana News

Targa Resources Corp. to Participate in J.P. Morgan Energy, Power and Renewables Conference

14.06.2024 - HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) - Targa Resources Corp. (NYSE: TRGP) ('Targa' or the 'Company') announced today that representatives from the Company will participate in investor meetings at the J.P. Morgan Energy, Power and Renewables ...

Via Renewables, Inc. Announces Completion of Merger - Vimarsana News

Via Renewables, Inc. Announces Completion of Merger

HOUSTON, TX / ACCESSWIRE / June 13, 2024 / Via Renewables, Inc. ("Via Renewables" or the "Company") (NASDAQ:VIA)(NASDAQ:VIASP), an independent retail energy services company, announced today the completion

Iteris Reports Record Fiscal 2024 Full Year Revenue of $172.0 million, Up 10% Year Over Year - Vimarsana News

Iteris Reports Record Fiscal 2024 Full Year Revenue of $172.0 million, Up 10% Year Over Year

Iteris, Inc. , the global leader in smart mobility infrastructure management, today reported financial results for its fiscal fourth quarter and full year ended March 31, 2024. Fiscal 2024 Fourth Quarter Financial Highlights Revenues of $42.8...

U.S. Food and Drug Administration Approves Augtyrotm (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors - Vimarsana News

U.S. Food and Drug Administration Approves Augtyrotm (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that...

TE Connectivity shareholders approve proposals at Special General Meeting - Vimarsana News

TE Connectivity shareholders approve proposals at Special General Meeting

TE Connectivity shareholders approve proposals at Special General Meeting